BioView and Abbott to Collaborate on Automated FISH Scanning for Vysis ALK Probe Kit
REHOVOT, Israel, November 28, 2012 /PRNewswire/ –
BioView Ltd. (TASE: BIOV), announced today that they have entered into an agreement
with Abbott to collaborate on the development of an automated scanning solution to detect
rearrangements of the anaplastic lymphoma kinase (ALK) gene in patients with advanced
non-small cell lung cancer (NSCLC).
Under terms of the agreement BioView will perform the appropriate studies to obtain
regulatory approval for its Duet Automated Scanner to include an indication for automated
imaging and analysis of Abbott’s Vysis ALK Break Apart FISH Probe Kit.
Abbott plans to utilize the BioView product in its own clinical trials for future
regulatory approval for end-to-end automation of the preparation, scanning and scoring of
formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer tissue specimens,
probed with the ALK Kit.
After receiving regulatory approvals, the parties plan to co-promote the BioView
product worldwide, in compliance with applicable regulatory rules.
In addition, the Companies are exploring the possibility of incorporating BioView
Scanning Automation to further automate Abbott’s future FISH assay development.
The Duet(TM) System is intended for in-vitro diagnostic use as an aiding tool to the
pathologist in the detection, classification and counting of cells of interest based on
color, intensity, size, pattern, and shape. The Duet[TM] has FDA clearances for the
automated imaging and analysis of:
- Hematopoietic cells stained by Giemsa stain, Immunohistochemistry or ISH (with bright field and fluorescent) prepared from cell suspension - Amniotic cells stained by FISH (using direct labeled DNA probes for chromosomes X, Y, 13, 18 and 21) - Cells in urine specimens, stained by FISH using the Vysis UroVysion[TM] Bladder Cancer Recurrence Kit - FFPE breast tissue specimens probed by the Vysis(R) PathVysionTM HER-2 DNA Probe Kit.
About BioView Ltd.
Established in 2000, and led by an expert team of biologists, software engineers and
physicists, BioView develops, manufactures and supplies cell imaging equipment, biological
kits and software to medical institutes and universities. BioView is a publicly traded
company on the Israeli Stock exchange, and currently has strategic collaborations underway
with international scientific leaders and institutions. For more information about the
BioView technology, and press related issues, please contact firstname.lastname@example.org or
visit our website at http://www.bioview.co.il.
Contact Information: BioView Dr. Alan Schwebel President and CEO Tel: +972-8-936-6868 email@example.com
SOURCE BioView Ltd